Complete breakdown of the REDUCE-IT trial results for icosapent ethyl, including primary and secondary MACE endpoints, hazard ratios with confidence intervals, Kaplan-Meier time-course data, and prespecified subgroup analyses.
Deep-dive into REDUCE-IT pre-specified and post-hoc subgroup analyses for icosapent ethyl (Vascepa), examining differential MACE reduction by age, sex, BMI, baseline triglycerides, race, and other clinical variables.
A deep dive into the REWIND trial's 12% MACE reduction with dulaglutide and what it means for real-world prescribing in type 2 diabetes, including guideline updates, patient selection, and primary prevention implications.
A critical analysis of the REWIND cardiovascular outcomes trial for dulaglutide, covering enrollment biases, generalizability gaps, statistical nuances, and post-publication commentary.
A plain-English deep dive into the REWIND cardiovascular outcomes trial for dulaglutide (Trulicity) in type 2 diabetes, covering methodology, results, limitations, and clinical implications.
REWIND trial results: dulaglutide cut three-point MACE by 12% (HR 0.88, 95% CI 0.79-0.99) over 5.4 years in 9,901 patients, per the 2019 Lancet publication.
A deep-dive into the SCALE Obesity trial of liraglutide 3.0 mg, examining how its results reshaped weight-management guidelines, prescribing patterns, and real-world patient selection.
A deep dive into the SCALE Obesity trial's randomization, blinding, inclusion criteria, statistical framework, and comparator design for liraglutide 3.0 mg in chronic weight management.
A deep-dive into the SCALE Obesity and Prediabetes RCT (2015), explaining how liraglutide 3.0 mg demonstrated meaningful weight loss versus placebo over 56 weeks and what it means for clinical practice.
How the SELECT trial's 20% MACE reduction with semaglutide 2.4 mg reshapes prescribing for patients with obesity and established cardiovascular disease, even without diabetes.
What the SELECT trial's follow-up and extension analyses reveal about the durability of semaglutide 2.4 mg's cardiovascular benefits, long-term safety signals, and unanswered questions beyond the primary endpoint.
A plain-English deep dive into the SELECT trial, the landmark RCT that proved semaglutide 2.4 mg reduces heart attacks and strokes in people with obesity and existing cardiovascular disease, even without diabetes.
A deep-dive into the SELECT trial's primary and secondary endpoint results for semaglutide 2.4 mg, including effect sizes, confidence intervals, subgroup analyses, and the time-course pattern of cardiovascular benefit.
Deep dive into the SELECT trial's pre-specified and post-hoc subgroup analyses for semaglutide 2.4 mg, examining differential MACE reduction by age, sex, BMI, race, and baseline biomarkers in patients with overweight/obesity and established cardiovascular disease.
A critical appraisal of the 2018 Sinclair low-dose oral minoxidil study for androgenetic alopecia, covering enrollment biases, follow-up gaps, statistical weaknesses, and generalizability concerns.
Deep-dive into the TRAVERSE bone fracture substudy's long-term follow-up findings, the 43% fracture increase signal with testosterone, durability of harm, and post-trial implications for TRT prescribing in older men.
A deep methodological analysis of the TRAVERSE Bone Fracture Substudy showing 43% increased fracture risk with testosterone in older hypogonadal men, examining randomization, blinding, endpoint adjudication, statistical frameworks, and what these design choices mean for clinical interpretation.
Deep-dive into the TRAVERSE bone fracture substudy results showing a 43% increase in fractures with testosterone replacement therapy in older men, including effect sizes, confidence intervals, subgroup analyses, and time-course patterns.
Detailed breakdown of pre-specified and post-hoc subgroup analyses from the TRAVERSE Bone Fracture Substudy, examining which older hypogonadal men faced the greatest fracture risk increase with testosterone replacement therapy.
Deep-dive into published cost-effectiveness analyses of semaglutide 2.4 mg from STEP-1: cost per QALY, payer coverage gaps, list vs net pricing, and value calculations for patients considering treatment.
Deep-dive into STEP-1 follow-up and extension data for semaglutide 2.4 mg, covering weight regain after discontinuation, long-term safety signals, and durability of cardiometabolic benefits.
In STEP-1 (NEJM 2021), adults taking semaglutide 2.4 mg lost a mean 14.9% of body weight over 68 weeks vs 2.4% on placebo; about a third lost 20% or more.
A deep dive into the STEP-1 trial's primary and secondary endpoints for semaglutide 2.4 mg, including effect sizes, confidence intervals, response distribution, and week-by-week weight-loss trajectory.
Deep dive into STEP-1 pre-specified and post-hoc subgroup analyses by age, sex, BMI, race, and baseline biomarkers, revealing which patients lost the most weight on semaglutide 2.4 mg.
A detailed critique of the STEP-1 Extension trial examining enrollment biases, follow-up gaps, generalizability concerns, statistical caveats, and conflict-of-interest disclosures around semaglutide discontinuation and weight regain.
A detailed methodological analysis of the STEP-1 Extension trial examining weight regain after semaglutide discontinuation, covering randomization, estimand framework, statistical approach, and interpretive implications.
A deep-dive into the STEP-1 Extension trial showing two-thirds of semaglutide weight loss was regained within one year of stopping treatment, confirming obesity requires ongoing pharmacotherapy.
Deep-dive into the STEP-1 Extension trial results showing weight regain after semaglutide 2.4 mg discontinuation, with effect sizes, secondary endpoints, and time-course analysis.
Deep-dive into STEP-1 Extension pre-specified and post-hoc subgroup analyses by age, sex, BMI, baseline biomarkers, and race/ethnicity, examining differential weight regain after semaglutide discontinuation.
How the STEP-2 trial reshaped prescribing for semaglutide 2.4 mg in type 2 diabetes, which guidelines responded, and what clinicians should consider for patients outside the trial population.
A critical analysis of the STEP-2 semaglutide trial in type 2 diabetes, covering enrollment biases, generalizability gaps, statistical caveats, conflict-of-interest disclosures, and post-publication commentary.
Deep-dive into published cost-effectiveness analyses of semaglutide 2.4 mg from the STEP-2 trial in type 2 diabetes, including cost per QALY, payer coverage, and real-world pricing.
A deep-dive overview of the STEP-2 randomized controlled trial testing semaglutide 2.4 mg for weight loss in adults with type 2 diabetes, including methodology, results, limitations, and clinical implications.
Complete breakdown of the STEP-2 trial results for semaglutide 2.4 mg in type 2 diabetes, including primary and secondary endpoints, confidence intervals, response distribution, and time-course data.
Deep-dive into STEP-2 pre-specified and post-hoc subgroup analyses for semaglutide 2.4 mg in type 2 diabetes, examining differential weight loss by age, sex, BMI, race, and baseline biomarkers.
How the STEP-3 trial of semaglutide 2.4 mg plus intensive behavioral therapy reshapes prescribing decisions, guideline recommendations, and real-world obesity management protocols.
A deep-dive into the enrollment biases, generalizability gaps, statistical caveats, and conflict-of-interest issues in the STEP-3 semaglutide 2.4 mg + intensive behavioral therapy trial.
Deep-dive into STEP-3 follow-up and extension findings for semaglutide 2.4 mg plus intensive behavioral therapy, covering weight regain after discontinuation, durability signals, and long-term safety.
A detailed methodology breakdown of the STEP-3 trial (semaglutide 2.4 mg + intensive behavioral therapy), covering randomization, blinding, estimand framework, inclusion criteria, and how each design choice shapes clinical interpretation.
A deep-dive overview of the STEP-3 trial (2021): semaglutide 2.4 mg combined with intensive behavioral therapy produced 16.0% weight loss vs 5.7% with placebo plus IBT at 68 weeks in adults with overweight or obesity.
Complete breakdown of the STEP-3 trial's primary and secondary endpoints for semaglutide 2.4 mg plus intensive behavioral therapy, including effect sizes, confidence intervals, response distribution, and time-course data.
Deep dive into STEP-3 pre-specified and post-hoc subgroup analyses for semaglutide 2.4 mg plus intensive behavioral therapy, examining differential responses by age, sex, BMI, race, and baseline cardiometabolic markers.
A deep-dive into the STEP-5 trial's 104-week semaglutide data and what it means for real-world prescribing, guideline updates, and long-term obesity pharmacotherapy.
A critical appraisal of the STEP-5 semaglutide trial, covering enrollment biases, generalizability gaps, statistical caveats, conflict-of-interest concerns, and what peer commentary revealed about the 104-week weight-loss data.
A clinical-research deep dive into the STEP-5 trial design, randomization, estimand framework, and statistical choices behind the 104-week semaglutide weight-loss result.
A deep-dive into the STEP-5 randomized controlled trial examining semaglutide 2.4 mg for long-term weight management over 104 weeks, including methodology, results, limitations, and clinical implications.
A deep dive into the STEP-5 trial results for semaglutide 2.4 mg, covering primary and secondary endpoints, effect sizes, confidence intervals, response distribution, and the 104-week time course of weight loss.
A clinical deep-dive into the methodological limitations, enrollment biases, generalizability gaps, and conflict-of-interest considerations of the STEP-8 head-to-head trial comparing semaglutide 2.4 mg to liraglutide 3.0 mg for weight management.
What happened when STEP-8 participants stopped semaglutide 2.4 mg or liraglutide 3.0 mg? Analysis of off-treatment weight regain, durability signals, and long-term safety from the first GLP-1 head-to-head obesity trial.
A deep dive into the STEP-8 trial design, randomization, blinding strategy, estimand framework, and statistical choices that shaped the semaglutide vs liraglutide head-to-head comparison.
A detailed plain-English breakdown of the STEP-TEENS trial, which tested semaglutide 2.4 mg in adolescents with obesity and found 16.1% weight loss versus 0.6% with placebo.
A clinical deep-dive into the SUNRISE-1 trial of lemborexant for insomnia, examining what the results mean for real-world prescribing decisions, guideline updates, and patient selection beyond the abstract.
A critical analysis of the SUNRISE-1 trial's enrollment biases, follow-up duration, generalizability gaps, statistical caveats, and conflict-of-interest considerations for lemborexant in insomnia.
Health-economic analysis of lemborexant based on SUNRISE-1 trial data: cost per QALY, payer coverage patterns, WAC vs net pricing, and patient-level value calculations for insomnia treatment.
Deep-dive into SUNRISE-1 long-term extension findings for lemborexant in insomnia: durability of sleep onset latency improvements, safety signals over 12 months, and what the follow-up data reveal about sustained efficacy.
A deep-dive into the SUNRISE-1 randomized controlled trial that tested lemborexant against placebo and zolpidem for insomnia, leading to FDA approval of a dual orexin receptor antagonist.
Deep-dive into SUNRISE-1 trial results for lemborexant (Dayvigo) in insomnia: primary and secondary endpoints, effect sizes, confidence intervals, time-course data, and response distribution analysis.
Deep-dive into SURMOUNT-1 follow-up and extension findings for tirzepatide, covering weight regain after discontinuation, durability of cardiometabolic benefits, and emerging long-term safety signals.
A detailed breakdown of SURMOUNT-1's randomization, blinding, estimand framework, and statistical design, and why each methodological choice matters for interpreting tirzepatide's 20.9% weight-loss result.
A plain-English deep dive into the SURMOUNT-1 trial, explaining how tirzepatide achieved up to 20.9% weight loss in adults with obesity and what that means for clinical practice.